Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Wednesday. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Down 1.3 %

TNXP opened at $0.31 on Wednesday. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.61. The company has a market capitalization of $57.94 million, a P/E ratio of -0.01 and a beta of 2.02. The stock’s fifty day moving average is $0.24 and its two-hundred day moving average is $0.36. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.